Granulocyte collection efficiency and yield are enhanced by the use of a higher interface offset during apheresis of donors given granulocyte-colony-stimulating factor

Transfusion
D AdkinsL T Goodnough

Abstract

Trials evaluating granulocyte transfusions for therapy of febrile neutropenia demonstrated mixed clinical results, which may in part be due to the low neutrophil cell dose of the transfused components. To optimize the latter variable, the effect of various interface offset (IO) settings during apheresis on granulocyte collection efficiency (GCE) and yield was determined in normal donors given granulocyte-colony-stimulating factor (G-CSF). Seventeen donors underwent 44 granulocyte collections performed with a continuous-flow blood cell separator with hetastarch infusion after stimulation with G-CSF (5 micrograms/kg/day). Apheresis was performed alternatively using one of three IO settings: IO = 15 (Group 1, n = 16), IO = 25 (Group 2, n = 12), and IO = 35 (Group 3, n = 13). The GCE and yield and changes in donor platelet count, hematocrit (Hct), and red cell (RBC) volume of the components were compared among the three groups. The mean GCE was greater (p = 0.006) during apheresis at an IO setting of 35 (60 +/- 12%) than at an IO setting of 15 (40 +/- 17%). The mean granulocyte yield (x10(10) per procedure was 10.8 +/- 2.95 at an IO setting of 35 and 7.73 +/- 4.02 at an IO setting of 15 (p = 0.08). In a multivariate linear regressi...Continue Reading

Citations

Feb 11, 2010·International Journal of Hematology·Akimichi OhsakaUNKNOWN Japan Society of Transfusion Medicine and Cell Therapy, Granulocyte Transfusion Task Force
Sep 16, 2000·Transfusion·T LightfootD F Stroncek
Feb 17, 2000·Current Opinion in Pediatrics·D C Dale, W C Liles
Jan 23, 1999·Current Opinion in Hematology·C A Schiffer
Oct 7, 2005·Clinical Chemistry and Laboratory Medicine : CCLM·Uwe SchwankeRainer Moog
Jun 24, 2004·Vox Sanguinis·H EinseleB Neumeister
Apr 16, 2013·Transfusion·Kristin ThorauschHalvard Bonig
Dec 22, 2000·Blood Reviews·D B Jendiroba, E J Freireich
May 10, 2005·Journal of Clinical Apheresis·Edwin A Burgstaler

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.